Allergan has reported sales of $3.6 billion for the first quarter ended March 31, up by 5 percent compared with the same quarter a year ago. The company said the increase was mainly driven by a strong performance in eyecare products, facial aesthetics and Botox therapeutic. Adjusted operating earnings from ...
Already an Eyewear Intelligence subscriber? Sign in here.
Buying a membership today will give you:
Or sign-up for a trial month for just 9,90€. To continue reading this article register now.